Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Management of Rosuvastatin Therapy in Patients with Elevated Liver Function Tests

Threshold for Holding Rosuvastatin

  • For asymptomatic patients with elevated liver function tests (LFTs), the American College of Cardiology recommends continuing rosuvastatin with close monitoring if AST/ALT is less than 3 times the upper limit of normal (ULN), and considering dose reduction or temporary discontinuation if AST/ALT is greater than or equal to 3x ULN 1
  • The European Respiratory Journal suggests discontinuing rosuvastatin until liver function returns to normal if AST/ALT is greater than 5x ULN 2

Special Populations Where Statins Can Continue

  • For patients with non-alcoholic fatty liver disease (NAFLD), statins are not contraindicated and may improve liver enzyme elevations, according to the Clinical and Molecular Hepatology 3
  • The American Heart Association recommends aggressive cardiovascular risk modification with statins in NAFLD patients, despite baseline elevated LFTs 3

Reinitiation Strategy After Holding

  • After holding rosuvastatin due to elevated LFTs, the European Respiratory Journal recommends waiting until transaminases return to baseline or less than 2x ULN before restarting 2
  • The American College of Cardiology suggests restarting at a lower dose if cardiovascular benefit outweighs risk, and monitoring LFTs more frequently after restarting 1